Trial · NCT03296163
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) at Week 18 | MB02 (Bevacizumab Biosimilar Drug) | 40.3 | 95% Confidence Interval 34.9 to 46.0 | Percentage of participants | |
| Objective Response Rate (ORR) at Week 18 | EU-approved Avastin® | 44.6 | 95% Confidence Interval 39.0 to 50.3 | Percentage of participants | |
| Progression-free Survival (PFS) | MB02 (Bevacizumab Biosimilar Drug) | 36.0 | 95% Confidence Interval 33.0 to 36.43 | weeks | |
| Progression-free Survival (PFS) | EU-approved Avastin® | 37.3 | 95% Confidence Interval 36.14 to 45.14 | weeks | |
| Overall Survival (OS) | MB02 (Bevacizumab Biosimilar Drug) | NA | 95% Confidence Interval NA to NA | weeks | |
| Overall Survival (OS) | EU-approved Avastin® | NA | 95% Confidence Interval NA to NA | weeks | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | MB02 (Bevacizumab Biosimilar Drug) | with ≥1 TEAE | 288 | participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | EU-approved Avastin® | with ≥1 TEAE | 288 | participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | MB02 (Bevacizumab Biosimilar Drug) | with ≥1 Grade 3 or 4 TEAE | 131 | participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | EU-approved Avastin® | with ≥1 Grade 3 or 4 TEAE | 125 | participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | MB02 (Bevacizumab Biosimilar Drug) | with ≥1 treatment-related TEAE | 264 | participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | EU-approved Avastin® | with ≥1 treatment-related TEAE | 270 | participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | MB02 (Bevacizumab Biosimilar Drug) | with ≥1 Grade 3 or 4 treatment-related TEAE | 98 | participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | EU-approved Avastin® | with ≥1 Grade 3 or 4 treatment-related TEAE | 91 | participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | MB02 (Bevacizumab Biosimilar Drug) | with at least one Serious TEAE | 58 | participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | EU-approved Avastin® | with at least one Serious TEAE | 54 | participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | MB02 (Bevacizumab Biosimilar Drug) | with ≥1 TEAE leading to discontinuation | 72 | participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | EU-approved Avastin® | with ≥1 TEAE leading to discontinuation | 63 | participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | MB02 (Bevacizumab Biosimilar Drug) | with ≥1 treatment-related TEAE leading to discontinuation | 42 | participants | |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | EU-approved Avastin® | with ≥1 treatment-related TEAE leading to discontinuation | 33 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03296163/results